Opportunity Information: Apply for RFA HL 24 015
The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01 - Clinical Trial Not Allowed)" under Funding Opportunity Number RFA-HL-24-015. This funding is part of the LungMAP program, a long-running NIH effort focused on building an in-depth, publicly accessible reference atlas of the human lung. The central goal is to generate a comprehensive molecular and cellular map that researchers can use to better understand normal lung biology as well as the mechanisms that drive lung diseases, ultimately helping to pinpoint key cell types, molecular pathways, and potential therapeutic targets.
In practical terms, LungMAP is designed as an open-access, high-resolution resource that integrates information across multiple scales. The program aims to define lung cell populations not just by a single data type, but through a more complete profile that can include gene expression patterns, cellular or physiological states, three-dimensional spatial localization within lung structures, and how these features change across development and disease-related trajectories. The emphasis on "multi-scale" and "high-content" data signals that the program is intended to support modern atlas-building approaches that combine molecular profiling with spatial and structural context, so the resulting atlas functions as a reference platform that many different investigators can reuse and build upon.
This specific Phase 3 component is focused on a "Human Tissue Core," meaning the funded activity is expected to serve as a centralized resource that supports the broader LungMAP consortium by providing human lung tissue-related capabilities. While the provided summary does not list detailed tasks, a tissue core in an NIH consortium context typically implies standardized acquisition, handling, processing, quality control, annotation, and distribution or coordination of biospecimens and associated metadata, so that downstream consortium projects can generate consistent, comparable datasets. Because LungMAP is explicitly framed as an open-access resource, the tissue core function also generally aligns with the expectation that resulting materials, data, and accompanying documentation support broad reuse by the research community, consistent with NIH policies and program norms.
The award mechanism is a U01 cooperative agreement, which is distinct from a standard research grant in that NIH staff generally have substantial scientific and/or programmatic involvement during the project period. In other words, awardees should anticipate active coordination with NIH and other LungMAP components, shared milestones, and participation in consortium governance, data standards, and harmonized operating procedures. The opportunity is also labeled "Clinical Trial Not Allowed," which means the proposed work must not include a clinical trial as defined by NIH, even if it involves human biospecimens or human-derived data.
Key administrative details from the listing include an original application closing date of October 27, 2023, an award ceiling of $300,000, and classification within the NIH health activity category with CFDA number 93.838. The opportunity is listed as discretionary funding and uses the cooperative agreement funding instrument type. The "Expected Awards" field in the provided source data appears incomplete, so the number of awards should be confirmed in the full notice if needed.
Eligibility notes indicate that small businesses are included among eligible applicants in the provided source data. The opportunity also includes important restrictions and allowances related to foreign involvement: non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply as applicants, but non-domestic components of U.S. organizations are eligible, and foreign components (as NIH defines them in the NIH Grants Policy Statement) are allowed. In practice, that typically means a U.S.-based applicant organization may include certain project elements or collaborations that occur outside the United States, provided they are structured and justified as allowable foreign components and comply with NIH policy. For definitive interpretations and any additional eligibility categories beyond what is shown in the excerpt, applicants would need to rely on the full Notice of Funding Opportunity.
Overall, this funding opportunity supports the infrastructure and coordinated work needed to strengthen LungMAP Phase 3 by enabling high-quality human lung tissue resources that feed into an integrated atlas of lung development and biology. The program is positioned to accelerate discovery by standardizing inputs, enabling cross-project comparability, and producing reference-quality, openly accessible molecular and spatial maps that can be used to study both healthy lung function and disease processes.Apply for RFA HL 24 015
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01- Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838.
- This funding opportunity was created on 2023-09-06.
- Applicants must submit their applications by 2023-10-27. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is a National Institutes of Health (NIH) cooperative agreement opportunity titled "Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissue Core (U01 - Clinical Trial Not Allowed)" under Funding Opportunity Number (FON) RFA-HL-24-015.
Which NIH program is this associated with?
This opportunity is part of LungMAP, an NIH program focused on building an in-depth, publicly accessible reference atlas of the human lung.
What is the main goal of LungMAP described here?
The central goal is to generate a comprehensive molecular and cellular map of the human lung that researchers can use to better understand normal lung biology and mechanisms that drive lung diseases, including identifying key cell types, molecular pathways, and potential therapeutic targets.
What does it mean that LungMAP is an "open-access" atlas resource?
Based on the description provided, the atlas is intended to be publicly accessible and broadly reusable as a reference platform, so many different investigators can reuse and build upon the resource.
What does "multi-scale" and "high-content" mean in the context of LungMAP?
In this description, "multi-scale" and "high-content" refers to integrating information across multiple biological and structural layers, such as molecular profiling (for example, gene expression), cellular or physiological states, and spatial/three-dimensional localization within lung structures, including how those features change across development and disease-related trajectories.
What is being funded specifically in LungMAP Phase 3 under this notice?
This Phase 3 component is focused on a Human Tissue Core, meaning the funded activity is expected to serve as a centralized resource to support the broader LungMAP consortium by providing human lung tissue-related capabilities.
What kinds of activities are typically associated with a "Human Tissue Core" in an NIH consortium?
The summary does not list detailed tasks, but it indicates that a tissue core in this context typically implies standardized acquisition, handling, processing, quality control, annotation, and distribution or coordination of biospecimens and associated metadata so downstream projects can generate consistent, comparable datasets.
How does this Human Tissue Core support the overall LungMAP atlas effort?
By standardizing inputs (tissue handling, processing, metadata), a tissue core helps enable cross-project comparability and supports production of reference-quality molecular and spatial maps that can be integrated into an atlas used across the research community.
What is the award mechanism for this opportunity?
The mechanism is a U01 cooperative agreement.
How is a U01 cooperative agreement different from a standard NIH research grant?
A U01 is distinct from a standard research grant in that NIH staff generally have substantial scientific and/or programmatic involvement during the project period. Awardees should anticipate active coordination with NIH and other LungMAP components, shared milestones, and participation in consortium governance, data standards, and harmonized operating procedures.
Does this opportunity allow clinical trials?
No. The opportunity is labeled "Clinical Trial Not Allowed," meaning the proposed work must not include a clinical trial as defined by NIH, even if the work involves human biospecimens or human-derived data.
Can projects use human biospecimens under this opportunity?
The description indicates the work may involve human lung tissue and related human-derived data, but it must not include a clinical trial as defined by NIH.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-HL-24-015.
What is the application due date listed in the provided information?
The original application closing date listed is October 27, 2023.
What is the maximum (ceiling) award amount mentioned?
The listing includes an award ceiling of $300,000.
How many awards does NIH expect to make under this opportunity?
The "Expected Awards" field in the provided source data appears incomplete. The number of awards would need to be confirmed in the full Notice of Funding Opportunity.
What funding instrument type is used?
This opportunity uses the cooperative agreement funding instrument type.
How is this opportunity categorized administratively?
It is listed within the NIH health activity category, includes CFDA number 93.838, and is described as discretionary funding in the provided listing.
Are small businesses eligible to apply?
Yes. The eligibility notes in the provided source data indicate that small businesses are included among eligible applicants.
Are foreign (non-U.S.) institutions eligible to apply as the applicant organization?
No. Non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply as applicants, based on the information provided.
Can a U.S. organization include a non-domestic component in the project?
Yes. The provided information indicates that non-domestic components of U.S. organizations are eligible.
Are foreign components allowed under this opportunity?
Yes. Foreign components (as NIH defines them in the NIH Grants Policy Statement) are allowed, according to the eligibility notes provided.
What does it mean that foreign components are allowed but foreign institutions cannot apply?
As described, a U.S.-based applicant organization may include certain project elements or collaborations that occur outside the United States, provided they are structured and justified as allowable foreign components and comply with NIH policy. However, a non-U.S. institution cannot be the applicant organization.
What should applicants do to confirm eligibility details not fully spelled out in the summary?
For definitive interpretations and any additional eligibility categories beyond what is shown in the excerpt, applicants would need to rely on the full Notice of Funding Opportunity.
What kind of coordination should awardees expect as part of the LungMAP consortium?
The description indicates awardees should anticipate active coordination with NIH and other LungMAP components, shared milestones, and participation in consortium governance, data standards, and harmonized operating procedures.
Why is standardization emphasized in this opportunity?
Standardization is emphasized because the LungMAP atlas is meant to integrate datasets across projects and scales; consistent tissue handling, processing, quality control, and metadata help ensure datasets are comparable and can be combined into an integrated reference atlas.
What is the intended impact of this funding opportunity, based on the description?
The described intent is to support the infrastructure and coordinated work needed to strengthen LungMAP Phase 3 by enabling high-quality human lung tissue resources that feed into an integrated atlas, accelerating discovery by standardizing inputs and producing reference-quality, openly accessible maps for studying healthy lung function and disease processes.
Browse more opportunities from the same category: Health
Next opportunity: Research Experiences for Teachers (RET) in Engineering and Computer Science
Previous opportunity: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 24 015
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 24 015) also looked into and applied for these:
| Funding Opportunity |
|---|
| Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordinating Center (U24- Clinical Trial Not Allowed) Apply for RFA HL 24 016 Funding Number: RFA HL 24 016 Agency: National Institutes of Health Category: Health Funding Amount: $1,260,000 |
| High-Priority Behavioral and Social Research Networks??(R24 Clinical Trial Optional) Apply for RFA AG 24 034 Funding Number: RFA AG 24 034 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| State Dementia Care Research Center (U54 Clinical Trial Not Allowed) Apply for RFA AG 24 033 Funding Number: RFA AG 24 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Approaches to Identifying Preteen Suicide Risk and Protective Factors (R01 Clinical Trial Not Allowed) Apply for RFA MH 24 320 Funding Number: RFA MH 24 320 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: The Harmonized Cognitive Assessment Protocol (HCAP) Network (U24 Clinical Trial Not Allowed) Apply for RFA AG 24 035 Funding Number: RFA AG 24 035 Agency: National Institutes of Health Category: Health Funding Amount: $385,000 |
| Kenya Digital Health Ecosystem Activity Apply for 72061523RFI00001 Funding Number: 72061523RFI00001 Agency: Kenya USAID-Nairobi Category: Health Funding Amount: $20,000,000 |
| Data Coordinating Center for Approaches to Identifying Preteen Suicide Risk and Protective Factors (U24 Clinical Trial Not Allowed) Apply for RFA MH 24 322 Funding Number: RFA MH 24 322 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) Apply for PAR 23 300 Funding Number: PAR 23 300 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Computational Models of Influenza Immunity (U01 Clinical Trial Not Allowed) Apply for RFA AI 23 056 Funding Number: RFA AI 23 056 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Human Virome Program: Characterization of functional interactions between viruses and human and microbial hosts (U01 Clinical Trial Not Allowed) Apply for RFA RM 23 017 Funding Number: RFA RM 23 017 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Consortium Organization and Data Collaboration Center (CODCC) for the Human Virome Program (HVP) (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 016 Funding Number: RFA RM 23 016 Agency: National Institutes of Health Category: Health Funding Amount: $1,875,000 |
| Human Virome Characterization Centers (U54 Clinical Trial Not Allowed) Apply for RFA RM 23 019 Funding Number: RFA RM 23 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Human Virome Program: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed) Apply for RFA RM 23 018 Funding Number: RFA RM 23 018 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) Apply for PAR 23 305 Funding Number: PAR 23 305 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional) Apply for PAR 23 307 Funding Number: PAR 23 307 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R34 Clinical Trial Optional) Apply for RFA MH 24 332 Funding Number: RFA MH 24 332 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required) Apply for RFA MD 24 003 Funding Number: RFA MD 24 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed) Apply for PAR 23 301 Funding Number: PAR 23 301 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed) Apply for PAR 23 302 Funding Number: PAR 23 302 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Fc-Dependent Mechanisms of Antibody-Mediated Killing (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 054 Funding Number: RFA AI 23 054 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 24 015", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.